Patents by Inventor David W. Speicher
David W. Speicher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230063827Abstract: A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g.Type: ApplicationFiled: July 12, 2022Publication date: March 2, 2023Inventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Publication number: 20200033350Abstract: A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g.Type: ApplicationFiled: June 24, 2019Publication date: January 30, 2020Inventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Patent number: 10338076Abstract: A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g.Type: GrantFiled: January 31, 2018Date of Patent: July 2, 2019Assignee: The Wistar Institute of Anatomy and BiologyInventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Publication number: 20190177430Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating a cancer in a human subject wherein the human subject exhibits an elevated concentration of immunoglobulin E (IgE) in plasma obtained from the human subject, comprising the step of administering a therapeutically effective amount of a chemotherapeutic regimen to the human subject in need thereof. In some embodiments, the chemotherapeutic regimen includes doxorubicin monotherapy, trastuzumab monotherapy, doxorubicin and trastuzumab combination therapy, doxorubicin, cyclophosphamide, and 5-fluorouracil combination therapy, and doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab combination therapy.Type: ApplicationFiled: August 24, 2017Publication date: June 13, 2019Inventors: Bonnie Ky, David W. Speicher
-
Publication number: 20180238905Abstract: Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets.Type: ApplicationFiled: April 13, 2018Publication date: August 23, 2018Inventors: David W. Speicher, Kurt T. Barnhart, Lynn A. Beer
-
Publication number: 20180231559Abstract: A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g.Type: ApplicationFiled: January 31, 2018Publication date: August 16, 2018Inventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Patent number: 9983215Abstract: Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of the selected genes, gene fragments or transcripts or expression products, or changes in the expression levels of one or more of proteins or peptide fragments, identified in Table 2 and FIGS. 8 and 9 herein. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid, preferably sera, of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy.Type: GrantFiled: December 21, 2016Date of Patent: May 29, 2018Assignees: The Wistar Institute of Anatomy and Biology, The Trustees of the University of PennsylvaniaInventors: David W. Speicher, Kurt T. Barnhart, Lynn A. Beer
-
Patent number: 9903870Abstract: A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g.Type: GrantFiled: October 3, 2013Date of Patent: February 27, 2018Assignee: The Wistar Institute of Anatomy and BiologyInventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Publication number: 20170184610Abstract: Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of the selected genes, gene fragments or transcripts or expression products, or changes in the expression levels of one or more of proteins or peptide fragments, identified in Table 2 and FIGS. 8 and 9 herein. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid, preferably sera, of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy.Type: ApplicationFiled: December 21, 2016Publication date: June 29, 2017Inventors: David W. Speicher, Kurt T. Barnhart, Lynn A. Beer
-
Patent number: 9568486Abstract: Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets.Type: GrantFiled: February 15, 2012Date of Patent: February 14, 2017Assignees: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David W Speicher, Kurt T. Barnhart, Lynn A. Beer
-
Publication number: 20150233930Abstract: A diagnostic reagent or device for determining the autophagy levels of cancer cells comprises a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying a biomarker selected from IL-8, IL-1?, DKK-3, FAM-3C and/or LIF, or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. Another reagent contains ligands to two or more of these biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents are useful in methods of measuring autophagy of cancer cells, e.g., melanoma and for monitoring cancer progression, chemoresistance, or predicting likely candidates for treatment with autophagy inhibitors.Type: ApplicationFiled: February 6, 2015Publication date: August 20, 2015Inventors: David W. Speicher, Adam Kraya, Ravi K. Amaravadi
-
Publication number: 20140274794Abstract: Methods and compositions are provided for diagnosing ovarian cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of ovarian cancer, or the identification of a risk of developing ovarian cancer, or enables the monitoring of the status of progression or remission of ovarian cancer in the subject followed during a therapeutic protocol.Type: ApplicationFiled: September 7, 2012Publication date: September 18, 2014Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: David W. Speicher, Hsin-Yao Tang, Lynn A. Beer
-
Publication number: 20140256586Abstract: Methods and compositions are provided for diagnosing colorectal cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of colorectal cancer, or the identification of a risk of developing colorectal cancer, or enables the monitoring of the status of progression or remission of colorectal cancer in the subject followed during a therapeutic protocol.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: The Wistar Institute of Anatomy and BiologyInventors: David W. Speicher, Wona Joo
-
Publication number: 20140121127Abstract: Methods and compositions are provided for diagnosing ovarian cancer in a mammalian subject, preferably in a serum or plasma sample of a human subject. The methods and compositions enable the detection or measurement in the sample or from a protein level profile generated from the sample, the protein level of one or more specified biomarkers. Comparing the protein level(s) of the biomarker(s) in the subject's sample or from protein abundance profile of multiple biomarkers, with the level of the same biomarker(s) or profile in a reference standard, permits the determination of a diagnosis of ovarian cancer, or the identification of a risk of developing ovarian cancer, or enables the monitoring of the status of progression or remission of ovarian cancer in the subject followed during a therapeutic protocol.Type: ApplicationFiled: October 29, 2013Publication date: May 1, 2014Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Publication number: 20140100130Abstract: A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers. Optionally, such reagent or device includes a signaling molecule and/or a substrate on which the ligand is immobilized. Other reagents and methods of diagnosing ovarian cancer include use of CLIC4 ligands and/or multiple tropomyosin ligands with an additional ovarian cancer biomarker. For example, CLIC4 combined with one or more of CLIC1 and/or one or multiple members of the tropomyosin family, e.g.Type: ApplicationFiled: October 3, 2013Publication date: April 10, 2014Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: David W. Speicher, Hsin Yao Tang, Lynn A. Beer
-
Publication number: 20120214685Abstract: Methods and compositions are provided for diagnosing ectopic pregnancy in a mammalian subject by detecting changes in expression of ISM2, ADAM12, PST1, PSG7, PST11, PSG9, PSG2 and other genes identified therein, including combinations thereof. A selected gene, gene transcript or protein/peptide expression product, or profiles or signatures formed by combinations of same, detected in a biological fluid of a subject, enables comparison of the corresponding genes, proteins or profiles from that of a reference or control having a normal intrauterine pregnancy. Detection of characteristic changes in the gene profile or protein expression signature of the subject is correlated with a diagnosis of ectopic pregnancy. Various compositions for use in such diagnosis include PCR primer-probe sets or ligands, labeled or immobilized, which are capable of detecting the changes in expression or translation of these targets.Type: ApplicationFiled: February 15, 2012Publication date: August 23, 2012Applicants: The Trustees of the University of Pennsylvania, The Wistar InstituteInventors: David W. Speicher, Kurt T. Barnhart, Lynn A. Beer
-
Publication number: 20030205471Abstract: The invention provides a novel solution isoelectric focusing device and method that can reproducibly fractionate charged molecules into well-defined pools. This approach can be applied to mixtures of charged molecules, such as eukaryotic proteome samples where reproducible resolution and quantitation of greater than 10,000 protein components is feasible.Type: ApplicationFiled: June 10, 2003Publication date: November 6, 2003Applicant: The Wistar InstituteInventors: David W. Speicher, Xun Zuo
-
Patent number: 6638408Abstract: The invention provides a novel solution isoelectric focusing device and method that can reproducibly fractionate charged molecules into well-defined pools. This approach can be applied to mixtures of charged molecules, such as eukaryotic proteome samples where reproducible resolution and quantitation of greater than 10,000 protein components is feasible.Type: GrantFiled: April 3, 2000Date of Patent: October 28, 2003Assignee: The Wistar InstituteInventors: David W. Speicher, Xun Zuo
-
Patent number: 5047512Abstract: Homogeneous cyclophilin, a soluble binding protein, having a specific binding activity of above 50 ug cyclosporin A per mg protein and a molecular weight of about 17,600 daltons, reversibly binds immunosuppressants or antibodies thereto such as cyclosporin or anti-cyclophilin. It is isolated from the cytosol of several different mammalian tissues and can be used in various diagnostic and purifications procedures.Type: GrantFiled: June 23, 1987Date of Patent: September 10, 1991Inventors: Robert E. Handschumacher, Matthew W. Harding, David W. Speicher
-
Patent number: 4722999Abstract: Homogeneous cyclophilin, a soluble binding protein, having a specific binding activity of above 50 ug cyclosporin A per mg protein and a molecular weight of about 17,600 daltons, reversibly binds immunosuppressants or antibodies thereto such as cyclosporin or anti-cyclophilin. It is isolated from thecytosol of several different mammalian tissues and can be used in various diagnostic and purifications procedures.Type: GrantFiled: May 3, 1985Date of Patent: February 2, 1988Assignee: Yale UniversityInventors: Robert E. Handschumacher, Matthew W. Harding, David W. Speicher